All In Biotech

Drug Trial Radar · NCT06628310

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)

Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 185 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

185

Actual

Start

Dec 13, 2024

Primary completion

Oct 2030

Study completion Oct 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan (ABBV-400) is given in combination with Fluorouracil, Leucovorin, and a programmed cell death receptor 1 (PD1) inhibitor Budigalimab. The combination (AFLB) will be given to adult participants to treat locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEA). Telisotuzumab Adizutecan (ABBV-400) and Budigalimab are investigational drugs being developed for the treatment of mGEA. Fluorouracil and Leucovorin are drugs approved for the treatment of mGEA. This study will be divided into two stages, with the first stage treating participants with increasing doses of ABBV-400 within the AFLB regimen until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into groups called treatment arms where one group will receive Budigalimab and FOLFOX (Fluorouracil, Leucovorin, and Oxaliplatin) . A further two treatment groups will receive AFLB, but with two optimized doses of ABBV-400 to allow for the best dose to be studied in the future. Approximately 180 adult participants with mGEA will be enrolled in the study in 51 sites worldwide. In the dose escalation stage, participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan (ABBV-400) within the AFLB regimen until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage, participants will receive FOLFOX or receive AFLB, but with one of two optimized doses of ABBV-400. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Esophageal Adenocarcinoma

Interventions

  • Telisotuzumab AdizutecanDrug

    Intravenous (IV) Infusion

  • BudigalimabDrug

    IV Infusion

  • FluorouracilDrug

    IV Infusion; IV Injection

  • LeucovorinDrug

    IV Infusion; IV Injection

  • OxaliplatinDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by InvestigatorTime frame: Through Study Completion, Approximately 6 Years
  2. Percentage of Participants with Objective Response (OR) as Assessed by InvestigatorTime frame: Through Study Completion, Approximately 6 Years

Locations

49 sites in 11 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center /ID# 268690

    Duarte, California

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 272630

    Irvine, California

  • UCLA - Santa Monica /ID# 270024

    Santa Monica, California

  • AdventHealth Orlando /ID# 268561

    Orlando, Florida

  • City Of Hope - Atlanta /ID# 280646

    Newnan, Georgia

  • Hattiesburg Clinic /ID# 268572

    Hattiesburg, Mississippi

  • Duke University Medical Center /ID# 268186

    Durham, North Carolina

  • Millennium Physicians /ID# 268540

    Houston, Texas

  • CHU de Liege /ID# 270223

    Liège, Belgium

  • Algemeen Ziekenhuis klina /ID# 268754

    Brasschaat, Antwerpen, Belgium

  • Universitair Ziekenhuis Leuven /ID# 269957

    Leuven, Vlaams-Brabant, Belgium

  • Princess Margaret Cancer Centre /ID# 268277

    Toronto, Ontario, Canada

  • Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 268763

    Montreal, Quebec, Canada

  • Jewish General Hospital /ID# 268413

    Montreal, Quebec, Canada

  • Beijing Cancer Hospital /ID# 268455

    Beijing, Beijing Municipality, China

  • Cancer Hospital Chinese Academy of Medical Sciences(Langfang) /ID# 277479

    Langfang, Hebei, China

  • Harbin Medical University Cancer Hospital /ID# 268452

    Harbin, Heilongjiang, China

  • Union Hospital - Tongji Medical College /ID# 268796

    Wuhan, Hubei, China

  • The first Affiliated Hospital, Zhejiang University School of Medicine. /ID# 268782

    Hangzhou, Zhejiang, China

  • Haematologisch-Onkologische Praxis Eppendorf /ID# 268024

    Hamburg, Germany

  • Universitaetsklinikum Freiburg /ID# 270407

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • TUM Klinikum rechts der Isar /ID# 267792

    Munich, Bavaria, Germany

  • Krankenhaus Nordwest /ID# 268462

    Frankfurt am Main, Hesse, Germany

  • Universitaetsklinikum Leipzig /ID# 270432

    Leipzig, Saxony, Germany

  • Shaare Zedek Medical Center /ID# 267752

    Jerusalem, Israel

  • Hadassah Medical Center-Hebrew University /ID# 267753

    Jerusalem, Israel

  • Meir Medical Center /ID# 267998

    Kefar Sava, Central District, Israel

  • Soroka Medical Center /ID# 268301

    Beersheba, Southern District, Israel

  • Tel Aviv Sourasky Medical Center /ID# 267755

    Tel Aviv, Tel Aviv, Israel

  • Aichi Cancer Center /ID# 268124

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East /ID# 268083

    Kashiwa-shi, Chiba, Japan

  • Shizuoka Cancer Center /ID# 268123

    Sunto-gun, Shizuoka, Japan

  • National Cancer Center Hospital /ID# 268648

    Chuo-Ku, Tokyo, Japan

  • The Cancer Institute Hospital Of JFCR /ID# 268656

    Koto-ku, Tokyo, Japan

  • Pan American Center for Oncology Trials - Rio Piedras /ID# 268833

    Rio Piedras, Puerto Rico

  • Hospital General Universitario Gregorio Maranon /ID# 270037

    Madrid, Spain

  • Complexo Hospitalario Universitario de Ourense /ID# 270042

    Ourense, Spain

  • Hospital Clinico Universitario de Valencia /ID# 270040

    Valencia, Spain

  • Hospital Universitario de Navarra /ID# 270119

    Pamplona, Navarre, Spain

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267672

    Kaohsiung City, Taiwan

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.